Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
NCT ID: NCT01102946
Last Updated: 2011-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2009-02-28
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
NCT01746563
PRP vs Bevacizumab for PDR Treatment
NCT02705274
Ranibizumab for Diabetic Traction Retinal Detachment
NCT01201161
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
NCT01941329
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT01489189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PRP plus ranibizumab
Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
Panretinal Photocoagulation
Panretinal photocoagulation with green laser according to ETDRS
Ranibizumab
Ranibizumab (Lucentis), intravitreal injections of 0.05ml
PRP
Patients will only be submitted to panretinal photocoagulation
Panretinal Photocoagulation
Panretinal photocoagulation with green laser according to ETDRS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Panretinal Photocoagulation
Panretinal photocoagulation with green laser according to ETDRS
Ranibizumab
Ranibizumab (Lucentis), intravitreal injections of 0.05ml
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High risk proliferative diabetic retinopathy
* Visual acuity ≥ 20/800
* No previous laser treatment for diabetic retinopathy
Exclusion Criteria
* Systemic thrombo-embolic events
* Uncontrolled systemic hypertension
* Conditions avoiding adequated documentation
* Previous eye surgery in the last 6 months before inclusion in the study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of São Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of São Paulo
Ribeirão Preto, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
article on Pubmed
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRaHi
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.